



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

7 October 2020
EMA/CAT/572076/2020
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 09-11 September 2020

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
1.4.	Adoption of the August 2020 Written Procedure	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.3.1.	Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102.....	6
2.3.2.	Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene - Orphan - EMEA/H/C/005321	6
2.3.3.	Valoctocogene roxaparvovec - Orphan - EMEA/H/C/004749	6
2.4.	Day 120 list of questions	6
2.4.1.	Idecabtagene vicleucel - Orphan - EMEA/H/C/004662	6
2.5.	Day 80 assessment reports	7
2.6.	Update on ongoing initial applications.....	7
2.6.1.	Lisocabtagene maraleucel- Orphan - EMEA/H/C/004731	7
2.7.	New applications	7
2.7.1.	Autologous human chondrocytes in vitro expanded - EMA/H/C/004598.....	7
2.8.	Withdrawal of initial marketing authorisation application	7
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	7
2.10.	GMP and GCP inspections requests.....	7
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	7
2.11.1.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0003/G	7
2.12.	Extension applications.....	8
2.13.	Other Post-Authorisation Activities	8
2.13.1.	Imlygic - talimogene laherparepvec - EMEA/H/C/002771/R/0039	8
2.13.2.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/ANX/002	8
2.13.3.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/010	8
2.13.4.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/011	8
2.13.5.	Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/012	9
2.13.6.	Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/REC/013	9

2.13.7.	Kymriah – tisagenlecleucel- Orphan – EMA/H/C/004090	9
---------	---	---

3. Certification of ATMPs 9

3.1.	Opinion	9
3.2.	Day 60 Evaluation Reports	9
3.3.	New Applications	9

4. Scientific Recommendation on Classification of ATMPs 10

4.1.	New requests – Appointment of CAT Coordinator	10
4.1.1.	3D bio-printed bionic pancreas composed of islets of Langerhans and non-viable printable porcine-derived matrix plus porcine-derived decellularized blood vessel – H0005801.....	10
4.1.2.	3D bio-printed bionic pancreas composed of insulin- and glucagon-releasing cells and non-viable printable porcine-derived matrix plus porcine-derived decellularized blood vessel – H0005802	10
4.1.3.	Recombinant serotype 9 adeno-associated virus (rAAV9) encoding a codon-optimised human CLN5 (neuronal ceroid lipofuscinosis-5) transgene – H00005800	10
4.2.	Day 30 ATMP scientific recommendation	10
4.2.1.	Recombinant serotype 9 adeno-associated virus (rAAV9) encoding a codon-optimised human CLN7 (neuronal ceroid lipofuscinosis-7) transgene - H0005770	10
4.2.2.	Allogeneic CRISPR/Cas9-mediated genetically modified CAR T-cells targeting CD70 – H0005771	11
4.2.3.	Umbilical cord derived CD34+ cells expanded and umbilical cord derived non-expanded CD34-cells – H0005772.....	11
4.2.4.	Autologous human endometrial stem cells – H0005773	11
4.2.5.	Autologous human T cells genetically modified ex vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) directed against G protein-coupled receptor family C group 5 member D (GPRC5D) – H0005774.....	11
4.2.6.	Autologous regulatory T lymphocytes (Treg), with the marker profile of CD3+, CD4+, CD25high, CD127-, FoxP3+ - H0004575/0002.....	12
4.2.7.	Adeno-associated viral vector serotype 9 encoding human ATP7B - H0005775	12
4.3.	Day 60 revised scientific recommendation (following list of questions)	12
4.3.1.	Irradiated allogeneic induced-pluripotent stem cells expressing pluripotent genes and cancer-specific embryonic neo-antigens – H0005108/0002	12
4.3.2.	Autologous adipose-derived mesenchymal stem cell , diabetic foot syndrome - H0005699	12
4.4.	Finalisation of procedure	13
4.4.1.	Recombinant adeno-associated viral vector (serotype 8) carrying an optimised gene for human cyclic nucleotide gated channel subunit alpha 3 (CNGA3) protein – H0005726.....	13
4.4.2.	Autologous naïve regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) to recognize the HLA-A*02 antigen - H0005713	13
4.4.3.	Live-attenuated, genetically modified Mycobacterium bovis expressing the gene coding for listeriolysin from Listeria monocytogenes – H0005714	13
4.5.	Follow-up and guidance	13

5. Scientific Advice 13

5.1.	New requests – appointment of CAT Rapporteurs	13
-------------	--	-----------

5.2.	CAT reports	13
5.3.	List of Issues	13
5.4.	Finalisation of SA procedures	14

6.	Pre-Authorisation Activities	14
-----------	-------------------------------------	-----------

6.1.	Paediatric investigation plans	14
6.2.	ITF briefing meetings in the field of ATMPs	14
6.3.	Priority Medicines (PRIME) – Eligibility requests	14
6.3.1.	Month 0 - Start of the procedure	14
6.3.2.	Month 1 – Discussion of eligibility	14
6.3.3.	Month 2 – Recommendation of eligibility.....	14
6.3.4.	Ongoing support.....	14

7.	Organisational, regulatory and methodological matters	14
-----------	--	-----------

7.1.	Mandate and organisation of the CAT	14
7.1.1.	CAT membership	14
7.1.2.	EMA’s decision on the management of committees’ meetings for the Q4 of 2020	15
7.1.3.	Strategic Review & Learning (virtual) meeting (SRLM) under the German presidency, 22 October 2020	15
7.2.	Coordination with EMA Scientific Committees	15
7.2.1.	CAT-PDCO interaction	15
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	15
7.3.1.	Summary of product characteristics Advisory Group - draft ONCWP/SmPC AG Mock-up of SmPC section 4.8 for anticancer medicines	15
7.3.2.	Reactivation of EMA/Committees’ working parties.....	16
7.3.3.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)	16
7.4.	Cooperation within the EU regulatory network	16
7.5.	Cooperation with international regulators	16
7.5.1.	ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan	16
7.5.2.	ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan	16
7.6.	CAT work plan	17
7.7.	Planning and reporting	17
7.7.1.	Planning estimates of forthcoming ATMP MAAs	17
7.8.	Others	17
7.8.1.	Presence of nitrosamine impurities in human medicinal products	17

8.	Any other business	17
-----------	---------------------------	-----------

9.	Explanatory notes	18
-----------	--------------------------	-----------

10.	List of participants	22
------------	-----------------------------	-----------

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The CAT agenda for 09-11 September 2020 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 15-17 July 2020 meeting were adopted.

1.4. Adoption of the August 2020 Written Procedure

The CAT minutes of 12-14 August 2020 were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

2.3.1. Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102

Accelerated assessment

Kite Pharma EU B.V.; treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Scope: List of outstanding issues

Action: for adoption

List of Questions adopted on 20.05.2020.

The Rapporteurs presented their assessment report.

The list of outstanding issues was adopted. The procedure is reverted to the standard timetable.

2.3.2. Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene - Orphan - EMEA/H/C/005321

Accelerated assessment

Orchard Therapeutics (Netherlands) BV; treatment of metachromatic leukodystrophy (MLD)

Scope: List of outstanding issues

Action: for adoption

List of Questions adopted on 20.03.2020.

The rapporteurs presented their assessment report.

The list of outstanding issues was adopted. The procedure is reverted to the standard timetable.

2.3.3. Valoctocogene roxaparvovec - Orphan - EMEA/H/C/004749

Accelerated assessment

BioMarin International Limited; treatment of haemophilia A

Scope: List of outstanding issues

Action: for adoption

List of Questions adopted on 24.04.2020.

The rapporteurs presented their assessment report.

The list of outstanding issues was adopted. The procedure is reverted to the standard timetable.

2.4. Day 120 list of questions

2.4.1. Idecabtagene vicleucel - Orphan - EMEA/H/C/004662

Accelerated assessment

Celgene Europe BV; treatment of multiple myeloma

Scope: Day 120 list of questions

Action: for adoption

The Rapporteur presented the draft list of questions.

The list of questions was adopted.

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Lisocabtagene maraleucel- Orphan – EMEA/H/C/004731

Accelerated assessment

Celgene Europe BV; intended for the treatment of relapsed / refractory aggressive large B-cell Non-Hodgkin's lymphoma (NHL) Scope: update **Action:** for information

CAT noted the information.

2.7. New applications

2.7.1. Autologous human chondrocytes in vitro expanded – EMA/H/C/004598

Scope: timetable for assessment

Action: for adoption

The timetable was adopted.

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0003/G

AveXis EU Limited

Rapporteur: Hans Ovelgönne

Scope: Quality

Action: for adoption

CAT adopted a request for supplementary information.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/R/0039

Amgen Europe B.V.

Rapporteur: Olli Tenhunen, Co-Rapporteur: Rune Kjekken, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: 5-year Renewal of Marketing Authorisation. Opinion

Action: for adoption

Request for Supplementary Information adopted on 20.05.2020.

The renewal opinion was adopted.

2.13.2. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/ANX/002

AveXis EU Limited

Rapporteur: Hans Ovelgönne, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Rapporteur's Assessment Report

From initial MAA: Non-interventional post-authorisation efficacy study (PAES) - Study no. AVXS-101-RG-001: In order to further characterise and contextualise the outcomes of patients with a diagnosis of spinal muscular atrophy (SMA), including long-term safety and efficacy of Zolgensma, the MAH should conduct and submit the results of a prospective observational registry AVXS-101-RG-001 according to an agreed protocol.

Action: for adoption

CAT agreed the request for supplementary information.

2.13.3. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/010

AveXis EU Limited

Rapporteur: Hans Ovelgönne, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Rapporteur's Assessment Report - quality

Action: for adoption

The Rapporteur's assessment report was agreed.

2.13.4. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/011

AveXis EU Limited

Rapporteur: Hans Ovelgönne, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Rapporteur's Assessment Report - quality

Action: for adoption

The Rapporteur's assessment report was agreed.

2.13.5. Zolgensma - onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/REC/012

AveXis EU Limited

Rapporteur: Hans Ovelgönne, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Rapporteur's Assessment Report – quality

Action: for adoption

The Rapporteur's assessment report was agreed.

2.13.6. Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/REC/013

bluebird bio (Netherlands) B.V

Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik

Scope: Rapporteur's Assessment Report - quality

Action: for adoption

The Rapporteur's assessment report was agreed.

2.13.7. Kymriah – tisagenlecleucel- Orphan – EMA/H/C/004090

Novartis Europharm Limited

Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang

Scope: quality

Action: for discussion

The Rapporteur provided feedback

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. New requests – Appointment of CAT Coordinator

4.1.1. 3D bio-printed bionic pancreas composed of islets of Langerhans and non-viable printable porcine-derived matrix plus porcine-derived decellularized blood vessel – H0005801

Intended for the treatment of late-chronic pancreatitis

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.2. 3D bio-printed bionic pancreas composed of insulin- and glucagon-releasing cells and non-viable printable porcine-derived matrix plus porcine-derived decellularized blood vessel – H0005802

Intended for the treatment of brittle diabetes mellitus type I

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.1.3. Recombinant serotype 9 adeno-associated virus (rAAV9) encoding a codon-optimised human CLN5 (neuronal ceroid lipofuscinosis-5) transgene – H00005800

Intended for the treatment of neuronal ceroid lipofuscinosis type 5

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Recombinant serotype 9 adeno-associated virus (rAAV9) encoding a codon-optimised human CLN7 (neuronal ceroid lipofuscinosis-7) transgene - H0005770

Intended for the treatment of neuronal ceroid lipofuscinosis type 7

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.2. Allogeneic CRISPR/Cas9-mediated genetically modified CAR T-cells targeting CD70 – H0005771

Intended for the treatment of renal cell carcinoma and haematological malignancies

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.3. Umbilical cord derived CD34+ cells expanded and umbilical cord derived non-expanded CD34- cells – H0005772

Intended for the treatment in haematopoietic stem cell transplantation

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.4. Autologous human endometrial stem cells – H0005773

Intended for the treatment of stem cell therapy for ovarian insufficiency includes diminished ovarian reserve (DOR), premature ovarian failure (POF), primary ovarian insufficiency (POI) and poor ovarian response (POR)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.5. Autologous human T cells genetically modified ex vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) directed against G protein-coupled receptor family C group 5 member D (GPC5D) – H0005774

Intended for the treatment of patients with relapsed or refractory multiple myeloma

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.6. Autologous regulatory T lymphocytes (Treg), with the marker profile of CD3+, CD4+, CD25high, CD127-, FoxP3+ - H0004575/0002

Intended for the treatment and prevention of progression of, multiple sclerosis (MS) [relapsing remitting (RRMS), primary progressing (PPMS), secondary progressing (SPMS)]

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.2.7. Adeno-associated viral vector serotype 9 encoding human ATP7B - H0005775

Intended for the treatment of Wilson disease

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3. Day 60 revised scientific recommendation (following list of questions)

4.3.1. Irradiated allogeneic induced-pluripotent stem cells expressing pluripotent genes and cancer-specific embryonic neo-antigens – H0005108/0002

Intended for the treatment malignant solid tumours including all epithelial cancers in sub-group type harbouring a stemness mesenchymal-like signature and haematopoietic malignancies

Scope: responses from the applicant to the LoQs. Revised ATMP scientific recommendation

Action: for adoption

CAT discussed the revised ATMP classification report incorporating the additional information provided by the applicant. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 25 September 2020.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

4.3.2. Autologous adipose-derived mesenchymal stem cell , diabetic foot syndrome - H0005699

Intended for the treatment of diabetic foot syndrome

Scope: awaiting responses from the applicant to the LoQs. Revised ATMP scientific recommendation

Action: for adoption

Postponed awaiting responses from the applicant.

4.4. Finalisation of procedure

4.4.1. Recombinant adeno-associated viral vector (serotype 8) carrying an optimised gene for human cyclic nucleotide gated channel subunit alpha 3 (CNGA3) protein – H0005726

Intended for the treatment of achromatopsia caused by mutations in the CNGA3 gene

Scope: the European Commission raised no comments. ATMP scientific recommendation

Action: for information

The information was noted.

4.4.2. Autologous naïve regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) to recognize the HLA-A*02 antigen - H0005713

Intended for the prevention of immune-mediated graft rejection in HLA-A*02 mismatched renal transplantation

Scope: the European Commission raised no comments. ATMP scientific recommendation

Action: for information

The information was noted.

4.4.3. Live-attenuated, genetically modified Mycobacterium bovis expressing the gene coding for listeriolysin from Listeria monocytogenes – H0005714

Intended for treatment of non-muscle invasive bladder cancer

Scope: the European Commission raised no comments. ATMP scientific recommendation

Action: for information

The information was noted.

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests – appointment of CAT Rapporteurs

Timetable:

-Final Briefing Package:	25.09.2020
-Start of the procedure at SAWP:	01.10.2020
-CAT report due by:	02.10.2020
-CAT recommendation:	09.10.2020

5.2. CAT reports

5.3. List of Issues

5.4. Finalisation of SA procedures

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	03.09.2020
SAWP recommendation:	01.10.2020
CAT recommendation:	09.10.2020
CHMP adoption of report and final recommendation:	15.10.2020

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Romania: Felicia Ciulu-Costinescu – membership mandate started on 6 August 2020

Romania: Simona Badoi – membership mandate ended on 5 August 2020

Czech Republic: Ondřej Palán – membership mandate ended on 2 September 2020

Action: for information

The information was noted. The CAT chair thanked Ondřej Palán for his contributions to the work of the CAT.

7.1.2. EMA's decision on the management of committees' meetings for the Q4 of 2020

CAT: Martina Schüssler-Lenz

Scope: plan for the running of CAT meetings in October, November and December 2020

Action: for information

The information was noted.

7.1.3. Strategic Review & Learning (virtual) meeting (SRLM) under the German presidency, 22 October 2020

CAT: Martina Schüssler-Lenz, Egbert Flory

Scope: topics for the SRLM agenda:

Morning session: CAT-PDCO-PRAC joint meeting

Afternoon session: CAT-only meeting

Action: for discussion

The draft agenda of the CAT-only meeting and of the CAT-PDCO-PRAC joint meeting was presented. To further develop the agenda for the joint meeting, a teleconference (Adobe Connect) with all interested CAT members will be organised .

7.2. Coordination with EMA Scientific Committees

7.2.1. CAT-PDCO interaction

CAT: Martina Schüssler-Lenz

Scope: CAT participants to the brainstorming meeting to be held .

Action: for appointment

Note: following CAT members will, together with the CAT chair and vice-chair, attend the brainstorming meeting: Maja Sommerfelt, Claire Beuneu.

PDCO group:

-Koen Norga (PDCO Chair)

-Sabine Scherer (PDCO Vice Chair)

-Karen van Melderren (Non-clinical expert)

-Sylvie Benchetrit (Clinical expert)

CAT agreed with the appointment of the two CAT members. Feedback from the meeting will be provided at the October 2020 CAT meeting.

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Summary of product characteristics Advisory Group - draft ONCWP/SmPC AG Mock-up of SmPC section 4.8 for anticancer medicines

CAT/CHMP members: Bruno Sepodes, Jan Müller-Berghaus, John-Joseph Borg, Romaldas Mačiulaitis, Sol Ruiz

Scope: CHMP's request that the CAT be consulted and questioned the need for specific or separate guidance for ATMPs.

Action: for information

Note:

-a Eudralink package with the mock-up was sent to CAT members on 27 July 2020. Comments on the draft mock-up to be sent by 07 September 2020.
-CHMP at its ORGAM July 2020 meeting concluded that this topic comes back to their ORGAM agenda, once CHMP and CAT have had one month to comment.

Further to a presentation of the activity by EMA to develop a mock-up (low level template) for section 4.8 of the SmPC for oncology products, CAT members reflected if the proposals would be relevant to ATMPs, or if optional wording is needed (taking into account that ATMPs in this therapeutic area are for single administration, will require lymphodepletion, very specific products with a specific safety profile). It was proposed to provide feedback on ATMP specific additions to the mock-up.

7.3.2. Reactivation of EMA/Committees' working parties

CAT: Martina Schübler-Lenz

Scope: reactivation of EMA Working Parties – CAT perspective

Action: for information

The CAT chair introduced the topic. The information was noted.

7.3.3. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope:

-Meeting report PCWP HCPWP meeting 2 June 2020

-Meeting report PCWP HCPWP meeting on ICH 3 June 2020

-Meeting report PCWP HCPWP meeting 24 June 2020

-Draft Agenda [Workshop on the application of the General Data Protection Regulation \(GDPR\) in the area of health and Secondary Use of Data for Medicines and Public Health Purposes](#) – 23 September 2020

-Draft [Workshop on benefit-risk of medicines used during pregnancy and breastfeeding](#) – 22 September 2020

Action: for information

The information was noted.

7.4. **Cooperation within the EU regulatory network**

No items

7.5. **Cooperation with international regulators**

7.5.1. ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan

CAT: Ilona Reischl

Scope: feedback from the teleconference that took place on 23 July 2020

Action: for information

Following CAT members and experts attended the ATMP cluster TC: Ilona Reischl, Carla Herberts, Lisbeth Barkholt, Rune Kjekken, Nana Kruse, Juliane Rau (PEI), Louise Bang-Lauritsen (DKMA), Kristine Moll Harboe (DKMA), Eskild Coding Jorgensen (DKMA).

Feedback from the July 2020 ATMP cluster teleconference was provided.

7.5.2. ATMP cluster teleconference with FDA-USA, Health Canada and PMDA-Japan

CAT: Martina Schüssler-Lenz

Scope: agenda for the teleconference to take place on 17 September 2020

Action: for discussion

The agenda for the upcoming ATMP cluster was agreed. CAT members should inform CAT Secretariat if they plan to join this teleconference.

7.6. CAT work plan

No items

7.7. Planning and reporting

7.7.1. Planning estimates of forthcoming ATMP MAAs

Scope: Q3/2020 update of the business pipeline report for the human scientific committees

Action: for information

The information was noted.

7.8. Others

7.8.1. Presence of nitrosamine impurities in human medicinal products

CAT: Martina Schübler-Lenz

Scope: outcome of CHMP referral and applicability to ATMPs

Action: for information

Note: a presentation on nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients was given at the February 2020 CAT meeting.

EMA presented the outcome of the referral and how to apply this to biological medicinal products (including ATMPs): the risk of nitrosamine contamination needs to be address in the opinion of all MAAs. EMA was asked to develop a template (standard wording) for inclusion in the CAT assessment report (in conclusion on section 3.2.P).

8. Any other business

No items

Date of next CAT meeting:

07-09/10/2020

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan
 RP: Reflection paper
 RSI: Request for supplementary information
 SAs: Scientific Advices
 SAG-O: Scientific Advisory Group Oncology
 SAWP: Scientific Advice Working Party
 SR: Summary Report
 SWP: Scientific Working Party
 SME: Small and medium size enterprises
 SmPC: Summary of Products Characteristics
 TT: Timetable


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that

are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 09-11 September 2020 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	
Ilona Reischl	Member (Vice-Chair)	Austria	No interests declared	
Silke Dorner	Alternate	Austria	No interests declared	
Claire Beuneu	Member	Belgium	No interests declared	
Belaïd Sekkali	Alternate	Belgium	No interests declared	
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	
Mirna Golemovic	Member	Croatia	No interests declared	
Isavella Kyriakidou	Alternate	Cyprus	No interests declared	
Ivana Haunerova	Member	Czech Republic	No interests declared	
Anne Pastoft	Member	Denmark	No interests declared	
Toivo Maimets	Member	Estonia	No interests declared	
Pille Saalik	Alternate	Estonia	No interests declared	
Heli Suila	Member	Finland	No interests declared	
Olli Tenhunen	Alternate	Finland	No interests declared	
Violaine Closson	Member	France	No interests declared	
Jan Mueller-Berg haus	Member (CHMP co-opted member)	Germany	No interests declared	
Egbert Flory	Alternate (to CHMP representative)	Germany	No interests declared	
Angeliki Rompoti	Alternate	Greece	No interests declared	
Katalin Lengyel	Member	Hungary	No interests declared	
Maura O'Donovan	Member	Ireland	No interests declared	
Niamh	Alternate	Ireland	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Curran			applicable to this meeting	
Paolo Gasparini	Member	Italy	No interests declared	
Una Riekstina	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No interests declared	
Vitalis Briedis	Alternate (to CHMP representative)	Lithuania	No interests declared	
Guy Berchem	Member	Luxembourg	No restrictions applicable to this meeting	
John J. Borg	Member (CHMP member)		No interests declared	
Anthony Samuel	Alternate (to CHMP representative)	Malta	No interests declared	
Carla Herberts	Member	Netherlands	No interests declared	
Johannes Hendrikus Ovelgonne	Alternate	Netherlands	No interests declared	
Rune Kjeken	Member	Norway	No restrictions applicable to this meeting	
Maja Sommerfelt Grønvold	Alternate	Norway	No restrictions applicable to this meeting	
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	
Maria Isabel Borba Vieira	Alternate (to CHMP representative)	Portugal	No interests declared	
Felicia Ciulu-Costine scu	Member	Romania	No interests declared	
Lukas Slovak	Member	Slovakia	No interests declared	
Alexandra Padova	Alternate	Slovakia	No interests declared	
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	
Sol Ruiz	Member (CHMP	Spain	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	co-opted member)			
Marcos Timón	Alternate (to CHMP representative)	Spain	No interests declared	
Lisbeth Barkholt	Member	Sweden	No interests declared	
Maria Luttgen	Alternate	Sweden	No restrictions applicable to this meeting	
Bernd Gänsbacher	Member	Healthcare Professionals' Representative	No interests declared	
Alessandro Aiuti	Member	Healthcare Professionals' Representative	Restrictions identified	No participation to discussion, final deliberation or voting for agenda points: 2.3.2, 5.1.5, 6.3.2.7. Cannot act as Rapporteur for agenda point 5.1.5
Alessandra Renieri	Alternate	Healthcare Professionals' Representative	No interests declared	
Kerstin Sollerbrant	Member	Patients' Representative	No interests declared	
Lydie Meheus	Alternate	Patients' Representative	No interests declared	
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	
Roland Pochet	Alternate	Patients' Representative	No interests declared	
Catherine Milne	Observer/Alternate	European Directorate for the Quality of Medicine & HealthCare(EDQM)	No interests declared	
Barbara Bonamassa	Expert - via telephone*	AIFA-IT	No interests declared	
Svetlana Lorenzano	Expert - via telephone*	AIFA-IT	No restrictions applicable to this meeting	
Antonella Isgrò	Expert - virtual	AIFA-IT	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Gabriele Ruppert-Seipp	Expert - virtual	PEI-DE	No interests declared	
Leon Bongers	Expert - virtual	CBG-MEB-NL	No interests declared	
Rou-Afza Gunput	Expert - virtual	CBG-MEB-NL	No interests declared	
Loes den Otter	Expert - virtual	CBG-MEB-NL	No interests declared	
Marja van den Bovenkamp	Expert - virtual	CBG-MEB-NL	No interests declared	
Tuomo Lapveteläinen	Expert - virtual	FIMEA-FI	No interests declared	
Bjørn Bolstad	Expert - virtual	NOMA-NO	No restrictions applicable to this meeting	
Annika Folin	Expert - virtual	MPA-SE	No interests declared	
Daiana Vasilcanu	Expert - virtual	MPA-SE	No interests declared	
Matthias Renner	Expert - virtual	PEI-DE	No restrictions applicable to this meeting	
Maria Elisabeth Kalland	Expert - virtual	PEI-DE	No restrictions applicable to this meeting	
Tiina Palomäki	Expert - virtual	FIMEA-FI	No interests declared	
Johanna Lähteenvuori	Expert - virtual	FIMEA-FI	No interests declared	
Hilde Røshol	Expert - virtual	NOMA-NO	No restrictions applicable to this meeting	
Helga Haugom Olsen	Expert - virtual	NOMA-NO	No interests declared	
Brigitte Mueller	Expert - virtual	AGES-AT	No interests declared	
Marissa Opelt	Expert - virtual	AGES-AT	No interests declared	
Martin Walter	Expert - virtual	AGES-AT	No interests declared	
Andrea Laslop	Expert - virtual	AGES-AT	No interests declared	
Philipp Janesch	Expert - virtual	AGES-AT	No interests declared	
Florian	Expert - virtual	AGES-AT	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Klinglmueller				
Sussane Wolf	Expert - virtual	AGES-AT	No interests declared	
Tjerk Feenstra	Expert - virtual	AGES-AT	No restrictions applicable to this meeting	
Christine Vaculik	Expert - virtual	AGES-AT	No interests declared	
Alexandre Moreau	Expert - virtual	ANSM.SANTE-FR	No interests declared	
Marie-Thérèse Duffour	Expert - virtual	ANSM.SANTE-FR	No interests declared	
Frédérique d'Herbe	Expert - virtual	ANSM.SANTE-FR	No interests declared	
Sara Henry	Expert - virtual	ANSM.SANTE-FR	No interests declared	
Marion Perrin	Expert - virtual	ANSM.SANTE-FR	No interests declared	
Sigrid Klaar	Expert - virtual	MPA-SE	No restrictions applicable to this meeting	
Christoph Liebold	Expert - virtual	Regierung von Oberfranken	No restrictions applicable to this meeting	
Michael Rosu-Myles	Observer	Canada Health Care	No interests declared	
A representative from the European Commission attended the meeting				
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.